---
layout: default
title: Enalapril
parent: 僅模型預測 (L5)
nav_order: 121
evidence_level: L5
indication_count: 0
---

# Enalapril
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Enalapril: Evaluation on Hold — Insufficient Evidence Pack Data

## One-Sentence Summary

Enalapril is a well-established ACE (Angiotensin-Converting Enzyme) inhibitor widely used globally for hypertension, heart failure, and diabetic nephropathy.
However, this Evidence Pack contains **no TxGNN-predicted new indications**, **no original indication records**, and **critical data gaps** across all evaluation domains.
A complete drug repurposing evaluation **cannot be performed** until the missing data are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | None — `predicted_indications` array is empty |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction not yet generated; no supporting studies retrievable) |
| Philippines Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No repurposing rationale can be constructed because the `predicted_indications` array is empty in this Evidence Pack — TxGNN has not generated any candidate indications for Enalapril in the current dataset run.

Furthermore, the mechanism of action is flagged as a **high-severity data gap (DG002)**. Without MOA data, even a hypothesis-driven mechanistic bridge between an original indication and a potential new indication cannot be formulated.

The original approved indications field is also empty (`original_indications: []`), which may indicate that a regulatory data pull (e.g., from FDA Philippines or equivalent) was not completed before this pack was assembled.

---

## Clinical Trial Evidence

No TxGNN-predicted indication is available in this Evidence Pack. Indication-specific clinical trial evidence cannot be retrieved or presented.

---

## Literature Evidence

No TxGNN-predicted indication is available in this Evidence Pack. Indication-specific literature evidence cannot be retrieved or presented.

---

## Philippines Market Information

Enalapril is currently **not registered** in the Philippines under this Evidence Pack. No product authorizations were found.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|----------------------|--------------|-------------|---------------------|
| — | No registered products found | — | — |

> **Note:** Given that Enalapril is a long-established, off-patent ACE inhibitor available in most global markets, an independent verification with FDA Philippines (Food and Drug Administration, Philippines) is recommended, as the absence of records may reflect a data ingestion issue rather than a true absence from the market.

---

## Safety Considerations

Please refer to the package insert for safety information.

> All safety fields — key warnings, contraindications, and drug–drug interactions — are flagged as data gaps in this Evidence Pack. Specifically:
> - **DG001 (Blocking):** Package insert warnings and contraindications were not retrieved. This blocks entry into safety pre-screening (S1).
> - **DDI query:** Returned `not_found` (0 interactions recorded).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack is critically incomplete across all four evaluation pillars — regulatory data, TxGNN predictions, MOA, and safety — making it impossible to assess repurposing viability or generate a meaningful evidence-based recommendation at this time.

**To proceed, the following is needed:**

- **[Critical — Blocking]** Re-run the TxGNN prediction pipeline to populate `predicted_indications` for Enalapril (DB00584); the current empty array suggests the prediction step was not completed
- **[Critical — Blocking]** Resolve **DG001**: Download and parse the package insert PDF from the TFDA (or FDA Philippines equivalent) to extract key warnings and contraindications
- **[High]** Resolve **DG002**: Query the DrugBank API for Enalapril's mechanism of action to enable mechanistic plausibility analysis
- **[High]** Confirm original approved indications from at least one regulatory source (e.g., FDA Philippines, TFDA, EMA, or FDA USA)
- **[Medium]** Independently verify Philippines FDA registration status, as Enalapril is a widely available generic; a zero-registration result may indicate a data pipeline issue
- **[Medium]** Re-query DDI databases (e.g., DrugBank interactions endpoint) once the drug identity is confirmed, as the `not_found` status is unexpected for a drug with known interaction profiles
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

